La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Instem Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Instem ha un patrimonio netto totale di £54.6M e un debito totale di £1.0M, che porta il suo rapporto debito/patrimonio netto a 1.9%. Le sue attività totali e le sue passività totali sono rispettivamente £83.7M e £29.0M. L'EBIT di Instem è £6.3M rendendo il suo rapporto di copertura degli interessi 20.5. Ha liquidità e investimenti a breve termine pari a £8.4M.

Informazioni chiave

1.9%

Rapporto debito/patrimonio netto

UK£1.03m

Debito

Indice di copertura degli interessi	20.5x
Contanti	UK£8.44m
Patrimonio netto	UK£54.64m
Totale passività	UK£29.01m
Totale attività	UK£83.65m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Is Instem plc's (LON:INS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 03

Shareholders Are Thrilled That The Instem (LON:INS) Share Price Increased 190%

Jan 29

Calculating The Intrinsic Value Of Instem plc (LON:INS)

Dec 25

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { INS di £24.2M ) non coprono le sue passività a breve termine ( £25.5M ).

Passività a lungo termine: Le attività a breve termine di INS ( £24.2M ) superano le sue passività a lungo termine ( £3.5M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: INS ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di INS è aumentato da 0% a 1.9% negli ultimi 5 anni.

Copertura del debito: Il debito di INS è ben coperto dal flusso di cassa operativo ( 819.6% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di INS sono ben coperti dall'EBIT ( 20.5 x copertura).

Instem Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Instem's Shares to Trading on AIM Expected to Be Cancelled on 21 November 2023

Recent updates

Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline

ArchiMed SAS agreed completed the acquisition of Instem plc (AIM : INS) from group of sellers.

ArchiMed SAS agreed completed the acquisition of Instem plc (AIM : INS) from group of sellers.

Instem's Shares to Trading on AIM Expected to Be Cancelled on 21 November 2023

Here's Why We Think Instem (LON:INS) Might Deserve Your Attention Today

New minor risk - Earnings quality

ArchiMed SAS agreed to acquire Instem plc (AIM : INS) from group of sellers for approximately £190 million.

ArchiMed SAS agreed to acquire Instem plc (AIM : INS) from group of sellers for approximately £190 million.

An Intrinsic Calculation For Instem plc (LON:INS) Suggests It's 29% Undervalued

Less than half of directors are independent

Instem plc, Annual General Meeting, Jun 27, 2023

Ennov SA acquired Samarind Ltd from Instem plc (AIM:INS).

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Instem plc Announces Board and Committee Appointments

CEO & Executive Director exercised options and sold UK£143k worth of stock

Price target increased to UK£10.10

Less than half of directors are independent

Instem Unveils New Additions to Its Leading Computational Toxicology Software Suite

First half 2022 earnings released: EPS: UK£0.057 (vs UK£0.048 in 1H 2021)

Instem plc Announces Settlement of Historical Licence Dispute

Instem plc to Report First Half, 2022 Results on Sep 27, 2022

Instem plc, Annual General Meeting, Jun 09, 2022

European Medicines Agency Awards Research Grant to Instem

Instem plc Receives European Medicines Agency Research Grant

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Instem plc to Report Fiscal Year 2021 Results on Apr 26, 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director exercised options and sold UK£298k worth of stock

Instem plc Provides Revenue Guidance for the Year Ended 31 December 2021

Instem plc (LON:INS) Shares Could Be 45% Below Their Intrinsic Value Estimate

Instem plc Announces the Release of the Latest Edition of Its Leadscope Model Applier Computational Toxicology Software Solution

First half 2021 earnings released: EPS UK£0.048 (vs UK£0.095 in 1H 2020)

Instem plc's (LON:INS) Intrinsic Value Is Potentially 44% Above Its Share Price

Instem plc (AIM:INS) acquired PDS Pathology Data Systems Ltd. for CHF 14.2 million.

Instem plc (AIM:INS) acquired PDS Pathology Data Systems Ltd for CHF 14.2 million.

Full year 2020 earnings released: EPS UK£0.12 (vs UK£0.057 loss in FY 2019)

Instem plc (AIM:INS) acquired The Edge Software Consultancy Ltd. for £8.5 million.

Is Instem plc's (LON:INS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

New 90-day high: UK£5.20

Shareholders Are Thrilled That The Instem (LON:INS) Share Price Increased 190%

New 90-day high: UK£5.08

Calculating The Intrinsic Value Of Instem plc (LON:INS)

Instem plc Provides New Business Update

Instem Launches in Silico Toxicology Service

New 90-day low: UK£4.40

First half earnings released

New 90-day high - UK£5.45

Instem plc has completed a Follow-on Equity Offering in the amount of £15.750002 million.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane